Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This
typically relies on a measurable biochemical readout and accessible binding sites whose …

Most targeted protein degraders make use of what is called the ubiquitinprotea-some
system, which can be thought of as the recycling system of the cell. However, as will be …

Drug discovery efforts have traditionally focused on developing small molecules to directly
inhibit or modulate the enzymatic activity of disease-relevant proteins. However, the …

Traditional pharmaceutical drug discovery is almost exclusively focused on directly
controlling protein activity to cure diseases. Modulators of protein activity, especially …

With the discovery of PROteolysis TArgeting Chimeras (PROTACs) twenty years ago,
targeted protein degradation (TPD) has changed the landscape of drug development …

Protein degradation is a general process to maintain cell homeostasis. The intracellular
protein quality control system mainly includes the ubiquitin‐proteasome system and the …

Targeted protein degradation (TPD) involving chimeric molecules has emerged as one of
the most promising therapeutic modalities in recent years. Among various reported TPD …

Targeted protein degradation (TPD) is a promising approach that has the ability to address
disease-causing proteins. Compared to traditional inhibition, proteolysis targeting chimera …

Targeted protein degradation (TPD) is an emerging therapeutic strategy with the potential to
modulate disease-associated proteins that have previously been considered undruggable …